Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 3 19Phase 1 14Phase 1/2 4Phase 4 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Breast 2Thoracic 1

Conditions

Prostatic Neoplasms 4Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Male Urogenital Diseases 1Genital Diseases, Male 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × darolutamide × Genitourinary × Clear all
NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT04737109 2023-11-13

ADDItion

Big Ten Cancer Research Consortium

Phase 1/2 Terminated
6 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01317641 2017-03-29

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Orion Corporation, Orion Pharma

Phase 1/2 Completed
136 enrolled 28 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡